[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-cord-injury-sci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-cord-injury-sci":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,73,102,127,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100613306","home-neuromodulation-for-neurogenic-bladder-management-in-spinal-cord-injury-100613306",false,"NCT07264868","Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury","Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury: A Hybrid Implementation-Efficacy Trial","Inclusion Criteria:\n\n* Non-progressive chronic (\\>1 year) SCI\n* Neurologic level of injury T9 and above\n* Stable over active bladder (OAB) medications (≥3 months)\n* No contraindication to MRI (per MRI Safety Questionnaire)\n* English or Spanish speaking\n* Tolerate and be able to evoke toe flexion bilaterally with transcutaneous tibial nerve stimulation (tTNS) (self or assisted)\n* Pass the tTNS competency checklist to perform or direct performance of tTNS.\n\nExclusion Criteria:\n\n* Ongoing\u002Factive genitourinary oncologic diagnoses\n* History of other central nervous system disorder (CNS) disorders and\u002For peripheral neuropathy\n* Pregnancy or planning to become pregnant.\n* Lower Motor Neuron bladder\n* Restorative bladder surgery such as augmentation cystoplasty\n* Botulinum toxin-A injections in the bladder within 6 months of trial enrolment (injection in other sites is allowed)\n* Anticoagulation treatment or prophylaxis\n* Advanced peripheral vascular disease (gangrene, amputation, etc.)\n* History of intolerance to electrical stimulation, particularly of the leg","ALL","18 Years","75 Years",{"count":20,"type":21},21,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to determine the safety and efficacy of Injectrode Tibial Nerve Stimulation for bladder function in people with spinal cord injury.",[27,28],"Spinal Cord Injury (SCI)","Neurogenic Bladder (NB)","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":30,"type":33},{"date":36,"type":21},"2028-09-01",{"name":38,"class":39},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100611001","arc-im-therapy-to-support-and-promote-recovery-of-ambulatory-functions-in-people-with-subacute-and-chronic-spinal-cord-injury-100611001","NCT07234903","ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury","EIGER","Inclusion Criteria:\n\n1. Must be at least 18 years old and no older than 65 years old at the time of enrollment.\n2. Must be graded A, B, C, or D in the ASIA Impairment Scale (AIS).\n3. Must have a SCI level at T10 or higher as determined by ISNCSCI, with the region extending 6 cm above the tip of the conus remaining anatomically intact as determined by MRI.\n4. Must have sustained their injury either less than 6 weeks prior to baseline (Group \"Subacute SCI\"), or more than 1 year prior to enrollment (Group \"Chronic SCI\").\n5. Must be suffering from a SCI due to trauma.\n6. Must have a stable medical, physical and psychological condition as considered by the investigators and the delegated specialists.\n7. Must have residual upper limb function to use the arms for weight bearing support (as determined by functional demonstration).\n8. Must be able to understand and interact with the study team in German, French or English.\n9. Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments.\n10. Must provide Informed Consent as documented by signature prior to any study-related procedures.\n11. Must have an acceptable or highly effective method of contraception for women of childbearing capacity.\n\nExclusion Criteria:\n\n1. Must not be pregnant nor breastfeeding.\n2. Must not have brain damage.\n3. Must not have a history of epilepsy\n4. Must not have participated in another clinical study using drugs or medical devices within the 30 days preceding and during the present study.\n5. Must not have previously been injected with stem cells in the spinal cord.\n6. Must not have any diseases and conditions that would increase the morbidity and mortality of SCI surgery.\n7. Must not require ventilator support.\n8. Must not have any existing contraindication to mobility functions (e.g., unhealed bone fractures, central nervous system disorder, peripheral nerve disorder, etc.).\n9. Must not suffer from SCI from other etiology than trauma (ischemic, tumoral, autoimmune, etc.).\n10. Must not have any anatomical limitations in the implantation area as judged by the investigators (e.g., spinal stenosis, limiting protrusions, post-traumatic bone damage at area of implantation).\n11. Must not require the use of an intrathecal baclofen pump.\n12. Must not have any active implanted devices.\n13. Must not have any other conditions that would make the subject unable to participate in testing in the judgment of the investigators (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.).\n14. Must not be the investigator him\u002Fherself, his\u002Fher family members, employees or other dependent persons.","65 Years",{"count":50,"type":21},12,[24],"The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.",[54,55,56,57,58,27],"Spinal Cord Injury","SCI","SCI - Spinal Cord Injury","Subacute Spinal Cord Injury","Chronic Spinal Cord Injury",[55,54,60,61,62],"Epidural Electrical Stimulation","Spinal Cord Stimulation","ARC-IM Therapy","2026-04-16",{"date":65,"type":33},"2026-04-21",{"date":67,"type":21},"2026-04",{"date":69,"type":21},"2032-04",{"name":71,"class":39},"Ecole Polytechnique Fédérale de Lausanne",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":40},"100613928","phase-4-metformin-in-preventing-secondary-gliosis-following-acute-thoraco-lumbar-spinal-cord-injury-100613928","NCT07272967","Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury","Safety and Efficacy of Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury: A Randomized, Double-Blinded, Placebo-Controlled Study.","Inclusion Criteria:\n\n* Adults aged 18-65 years, who had acute, non-penetrating thoraco-lumbar SCI (T1-conus medullaris), with new neurological deficits.\n* Injury occurred within the past 24 hours before enrollment.\n* American Spinal Injury Association (ASIA) Impairment Scale grade B-D.\n* Able to undergo MRI of the spine.\n* Informed consent provided by patient or legal representative.\n\nExclusion Criteria:\n\n* Major spinal transaction or cervical spinal cord injury.\n* Prior spinal surgery or pre-existing spinal pathology (e.g., kyphosis, tumors).\n* Concomitant severe traumatic brain injury (Glasgow Coma Scale \\\u003C 13) or other CNS injury that would confound neurological assessment.\n* Known diabetes mellitus (type 1 or 2) or current use of metformin.\n* Penetrating spinal injury (e.g. gunshot, stab wound).\n* Implanted metallic devices or conditions precluding MRI.\n* Pregnancy or breastfeeding.\n* Severe comorbidities (e.g. end-stage liver disease, renal failure with eGFR\\\u003C30 mL\u002Fmin).\n* Known allergy to metformin.\n* Uncontrolled infection or sepsis at presentation.",{"count":81,"type":21},34,[83],"PHASE4","Background:\n\nSpinal cord injury (SCI) is a major global health problem, with thoraco-lumbar injuries often leading to paraplegia and incomplete neurological recovery. The glial scar, resulting from astrocyte activation at the injury site, constitutes a major barrier to axon regeneration. Given the limitations of current treatments, there is an urgent need for new interventions to improve outcomes. Metformin, a common drug for diabetes, shows promising potential as a neuroprotective agent in preclinical SCI models, where it improves motor function and reduces pain and glial scar formation. Its safety in acute neurological injury has also been supported in a recent human trial for severe traumatic brain injury.\n\nObjective:\n\nTo test the safety and efficacy of metformin in acute thoraco-lumbar SCI, focusing on neurological and functional outcomes as well as DTI metrics of spinal cord integrity.\n\nMethods. Study Design. Randomized, double-blinded, placebo-controlled study.\n\nPopulation:\n\nParticipants that will be admitted during the time of the study to Neurosurgery department at Menoufia University hospitals at Menoufia University.\n\nSetting:\n\nNeurosurgery department at Menoufia University hospitals at Menoufia University.\n\nKeywords:\n\nMetformin, spinal cord injury, gliosis, randomized controlled trial, neuroprotection",[27],[87,88,89,90,91],"Metformin","spinal cord injury,","gliosis",", randomized controlled trial","neuroprotection","NOT_YET_RECRUITING","2025-11-26",{"date":95,"type":33},"2025-12-09",{"date":97,"type":21},"2026-01-01",{"date":99,"type":21},"2026-02-01",{"name":101,"class":39},"Badr University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100590262","implant-for-walking-after-incomplete-sci-100590262","NCT06965127","Implant for Walking After Incomplete SCI","Enhancing Walking and Independence After Incomplete SCI With a Fully Implanted Neuroprosthesis","Inclusion Criteria:\n\n* Between the ages of 18-75\n* Non-ventilator dependent paralysis resulting from injuries such as: cervical\u002Fthoracic spinal cord injuries affecting the trunk and\u002For lower limbs\n* Impairment classification of AIS B, C, or D (preservation of sensation and\u002For some motor function) with weakness in trunk and\u002For lower extremity muscles\n* Unable to walk faster than 0.8m\u002Fs during a 10m walk test\n* Gait deviation such as reduced peak hip, knee, and\u002For ankle range of motion during stance or swing phases due to motor impairment\n* Time post injury greater than six months\n* Innervated and excitable lower extremity and trunk musculature\n* Adequate social support and stability\n* Willingness to comply with follow-up procedures\n* Appropriate body habitus (height and weight within acceptable limits as determined by study physician)\n* Neurologically stable as determined by a physician\n\nExclusion Criteria:\n\n* Significant fracture risk or history of spontaneous fractures\n* History of heterotopic ossification at the hip, knee, or ankle\n* Non-English speaking\n* Insufficient upper extremity function to use an assistive device (e.g. walker or cane)\n* Females who are pregnant\n* Current pressure injury that would be exacerbated by study activities\n* Uncontrolled spasticity that would interfere with study activities\n* Significant range of motion limitations that would compromise study activities\n* History of vestibular dysfunction, balance problems, or spontaneous falls\n* Disorder or condition that require MRI monitoring\n* Acute and\u002For untreated orthopedic issues that would prevent weight bearing or exercising implanted muscles such as a dislocation or fracture\n* Acute and\u002For chronic medical problems left untreated or not controlled that would increase risk by using stimulation such as cardiac abnormalities, immunological\u002Fpulmonary\u002Frenal\u002Fcirculatory compromise\n* Uncontrolled diabetes or hypertension\n* Presence of a demand pacemaker, cardiac defibrillator, or neuroprosthesis system with components in the legs\n* Any other medical or psychological condition that would be a contraindication\n\nImplant eligibility criteria\n\n• In addition to all of the above, the participant must be able to fully support their body weight in standing with an assistive device prior to implantation.",{"count":110,"type":21},5,[24],"This is a device study that will evaluate the effect of an implanted stimulator on improving walking in people with incomplete spinal cord injury. There are two phases in the study: 1) Screening - this phase determines if the individual is a good candidate to receive an implanted system, 2) Implantation, controller development, and evaluation - this phase includes implanting the device and setting the individual up for system use, creating controllers for walking, and evaluating the effect of the device over a couple years.",[27,114],"Gait",[116,117],"neuroprosthesis","implanted device","2025-11-20",{"date":93,"type":33},{"date":121,"type":33},"2025-08-27",{"date":123,"type":21},"2031-08",{"name":125,"class":126},"Louis Stokes VA Medical Center","FED",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":40},"100575422","safety-and-usability-of-the-atlas-2030-exoskeleton-in-pediatric-patients-with-spinal-cord-injury-100575422","NCT06772077","Safety and Usability of the ATLAS 2030 Exoskeleton in Pediatric Patients With Spinal Cord Injury","Inclusion Criteria:\n\n* Having a subacute or chronic spinal cord injury (SCI) and being clinically stable with a general condition good enough to participate in the therapeutic program with the ATLAS 2030.\n* Age between 3 and 14 years.\n* Medical authorization to perform standing and gait training with weight-bearing.\n* Consent from the participant or legal guardian to participate in the study.\n* Adequate level of acceptance and commitment from the family.\n\nInclusion criteria related to device characteristics:\n\n* Weight ≤ 35 kg.\n* Hip width ≤ 34 cm. It is advised that for measurements under 28 cm, verification should be performed to ensure there is no excessive base of support that might induce foot inversion in the standing position.\n* Femur length (distance from the greater trochanter to the lateral condyle of the femur) between 24 cm and 33 cm. Femur lengths shorter than 24 cm are acceptable as long as the hip motor of the device does not extend above the user's iliac crest, avoiding hypermobility of the lumbar spine.\n* Tibia length (distance from the lateral condyle to the lateral malleolus of the tibia) between 23 cm and 32 cm. Tibia lengths shorter than 23 cm are acceptable as long as they can be compensated with a lift and the user's ankle joint remains within the area of the ankle motor.\n* EU shoe size between 27 and 33.\n\nExclusion Criteria:\n\n* Impossibility for the family to complete treatment schedule planning.\n* Any contraindication for standing and\u002For walking.\n* Spasticity (Modified Ashworth Scale (MAS) = 4 in the lower limbs at the time of device use).\n* Joint contracture of the hip and\u002For knee \\> 20 degrees.\n* Need to walk with more than 9 degrees of hip abduction.\n* Need to walk with more than 9 degrees of dorsal or plantar ankle flexion, or inability to use an orthosis to achieve 90° at the ankle.\n* Severe skin lesions in areas of contact with the device.\n* Planned surgical intervention during the study period or previous orthopedic surgery on the spine and\u002For lower limbs contraindicating treatment.\n* Known advanced osteoporosis evidenced by bone densitometry, particularly with a history of prior fractures or fractures without trauma. Traumatic bone fractures in the lower limbs or pelvic girdle within the past 6 months.\n* Unstable fractures, joint dislocations, or other joint pathologies in the trunk and lower limbs contraindicating the treatment.\n* Severe rigid orthopedic deformities of the spine that prevent the use of the device.\n* Presence of frequent seizures, uncontrolled epilepsy, or difficult-to-control behavioral disorders.\n* Presence of decompensated heart or lung disease, or any other condition causing exercise intolerance.\n* Allergy to any of the materials used in the ATLAS 2030: cotton, nylon, polyester, polyamide, polyethylene, or polypropylene.","3 Years","14 Years",{"count":136,"type":21},20,[24],"The goal of this clinical trial is to analyze the usability and safety of the robotic gait ATLAS 2030 in a cohort of pediatric patients with Spinal Cord Injury, with the aim of extending its indication for use to pediatric spinal cord injury",[27],[54,141,142,143,144,145],"Rehabilitation","robotics","Gait Exoskeleton","children","ATLAS2030","2025-08-11",{"date":148,"type":33},"2025-08-14",{"date":150,"type":33},"2025-02-17",{"date":99,"type":21},{"name":153,"class":154},"MarsiBionics","INDUSTRY",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":40},"100593549","effect-of-transauricular-vagal-stimulation-on-cardiac-function-after-spinal-cord-injury-100593549","NCT07007884","Effect of Transauricular Vagal Stimulation on Cardiac Function After Spinal Cord Injury","The Effect of Transauricular Vagal Nerve Stimulation (taVNS) on Cardiac Autonomic Functions in Patients With Spinal Cord Injury","Inclusion Criteria:\n\n1. Aged between 18-60\n2. Having a traumatic spinal cord injury\n3. Cervical spinal cord injury patients with a history of autonomic dysreflexia\n4. At least 6 months after the injury\n5. Signing an informed consent form showing consent to participate in the study\n\nExclusion Criteria:\n\n1. Having a cardiac or neural pacemaker\n2. Presence of pregnancy\n3. Clinical coronary artery disease confirmed by invasive or coronary computed tomographic angiography\n4. History of acute coronary syndrome (unstable angina, myocardial infarction)\n5. Documented arrhythmia and\u002For use of antiarrhythmic drugs on ECG\n6. Diagnosis of hypertension and use of antihypertensive drugs\n7. Damaged skin lesion in the application area","60 Years",{"count":164,"type":21},30,[24],"The aim of this study is to investigate the effect of transauricular vagal nerve stimulation (taVNS) on cardiac autonomic functions in patients with spinal cord injury (SCI).",[27],[169],"vagus nerve stimülation","2025-06-03",{"date":172,"type":33},"2025-06-06",{"date":174,"type":33},"2024-03-20",{"date":176,"type":21},"2025-09-30",{"name":178,"class":39},"Gaziler Physical Medicine and Rehabilitation Education and Research Hospital"]